



## Atogepant (Qulipta™)


- Developed by Abbvie as an orally active Calcitonin Gene-Related Peptide (CGRP) receptor antagonist for the preventative treatment of migraines.
- The compound was approved in the US in 2021 and in the EU in 2023 for usage.

abbvie




Dubowchik, G. J. *Med. Chem.* **2020**, 63, 13, 6600–6623. <https://doi.org/10.1021/acs.jmedchem.9b01810>

## Early Med Chem Efforts to Access the $\delta$ -Lactam



US20160130273A1

## Efforts Towards the Spirocyclic System



## Completing the Synthesis

